Phase II study of FOLFIRI+biweekly cetuximab for KRAS wild type unresectable colorectal cancer.

Phase II study of FOLFIRI+biweekly cetuximab for KRAS wild type unresectable colorectal cancer. - Phase II study of FOLFIRI+biweekly cetuximab.

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011364

Enrollment

Registered

2013-08-03

Start date

2013-06-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: KRAS wild type colorectal cancer PS 0-1

Exclusion criteria

Exclusion criteria: PS 3

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Adverse event, Overall survival,Disease-free survival	—

Countries

Japan

Contacts

Public ContactKiyoshi Maeda

Osaka City University Hospital Department of Surgical Oncology

m1378386@med.osaka-cu.ac.jp06-6645-3838

Outcome results